Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01633489 · ClinicalTrials.gov registry record
Lysosomal Acid Lipase (LAL) Deficiency Registry
A clinical trial of Wolman Disease and Lysosomal Acid Lipase Deficiency, sponsored by Alexion Pharmaceuticals.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT01633489: Recruiting study of Wolman Disease and Lysosomal Acid Lipase Deficiency, sponsored by Alexion Pharmaceuticals.
NCT01633489 is a study of Wolman Disease and Lysosomal Acid Lipase Deficiency that is actively recruiting participants, run by Alexion Pharmaceuticals. The registered enrollment target is 300 participants, above the 110-participant average among 4 other Wolman Disease trials with a reported enrollment target (173% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01633489, a study of Wolman Disease and Lysosomal Acid Lipase Deficiency, is actively recruiting participants, sponsored by Alexion Pharmaceuticals.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary.
Conditions Studied
Study Locations (20)
Pennsylvania
- Clinical Trial Site - Philadelphia
- Clinical Trial Site - Philadelphia
- Clinical Trial Site - Philadelphia
Texas
- Clinical Trial Site - Houston
- Clinical Trial Site - Houston
- Clinical Trial Site - Snyder
Florida
- Clinical Trial Site - Miramar
- Clinical Trial Site - Orlando
New York
- Clinical Trial Site - New York
- Clinical Trial Site - The Bronx
Arizona
- Clinical Trial Site - Phoenix
California
- Clinical Trial Site - Stanford
Georgia
- Clinical Trial Site - Atlanta
Illinois
- Clinical Trial Site - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2013-05-30 |
| Est. Completion | 2029-08-30 |
What NCT01633489 shows while recruiting
NCT01633489 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 110-participant average among 4 other Wolman Disease trials with a reported enrollment target (173% higher).
The record links to 7 conditions, with Wolman Disease appearing as the primary indexed condition, and to 0 interventions.
NCT01633489 names 20 study sites across 14 states, led by Pennsylvania, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT01633489 about?
NCT01633489 is a clinical study titled "Lysosomal Acid Lipase (LAL) Deficiency Registry". This is an observational, multi-center, international disease registry designed to collect longitudinal data and create a knowledge base that will be utilized to improve the care and treatment of patients with LAL Deficiency. Participation in the Registry by both physicians and patients is voluntary...
What is the current status of trial NCT01633489?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2013-05-30. Estimated completion is 2029-08-30.
What conditions does trial NCT01633489 study?
This clinical trial studies the following conditions: Wolman Disease, Lysosomal Acid Lipase Deficiency, Cholesterol Ester Storage Disease, Acid Cholesteryl Ester Hydrolase Deficiency, Type 2, Acid Lipase Deficiency.
Who is sponsoring clinical trial NCT01633489?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01633489 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wolman Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry of Patients Diagnosed With Lysosomal Storage Diseases
RECRUITING
-
PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
RECRUITING · Phase 1
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
-
Stem Cell Transplant for Inborn Errors of Metabolism
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI